

Figure 1. Anti-Cln101 MAb Epitope Map




Figure 2. Detection of Cln101 in Normal and Cancer Serum Samples (primary panel)




Figure 3. Detection of Cln101 in Normal and Cancer Serum Samples (primary panel), Expanded Scale




Figure 4. Detection of Cln101 in Normal and Cancer Serum Samples (multiple panels)




Figure 5. Detection of Cln101 in Normal and Cancer Serum Samples (multiple panels), Expanded Scale




Figure 6. Detection of Cln101 in Normal and Cancer Serum Samples (master panel)




Figure 7. Detection of Cln101 in Normal and Cancer Serum Samples (master panel), Expanded Scale




Figure 8. Detection of Cln101 in Normal, Prostate Cancer and Prostate Benign Serum Samples




Figure 9. Detection of PSA in Normal, Prostate Cancer and Prostate Benign Serum Samples




Figure 10. Detection of Cln101 in Normal, Ovarian Cancer and Ovarian Benign Serum Samples




Figure 11. ROC Curves for Cln101 and PSA in Prostate Cancer vs. Normal Serum Samples




Figure 12. ROC Curves for Cln101 and PSA in Prostate Cancer and Benign Disease vs. Normal Serum Samples

